Latest news with #eyeHealth
Medscape
10 hours ago
- Health
- Medscape
Age Ups Risk for Acute Dacryocystitis in Blocked Tear Ducts
TOPLINE: Acute dacryocystitis (AD) is common in women and becomes increasingly likely with age, particularly in individuals with primary acquired obstruction of the tear duct. To prevent this condition, clinicians may recommend surgery to create a new drainage pathway for tears in individuals aged 70 years or older who present symptoms such as excessive tearing or cysts filled with mucus in the eye. METHODOLOGY: Researchers conducted a retrospective observational study to determine the risk factors for AD in adults with or without primary acquired obstruction of the tear duct. They analyzed 106 patients (mean age, 64.9 years; 81% women) diagnosed with AD between January 2000 and February 2020, considering only the first attack in case of recurrent episodes; those with congenital or secondary acquired obstruction of the tear duct were excluded. AD was diagnosed when a patient suddenly developed swelling, redness, or pain in the inner corner of the eye, with or without a history of excessive tearing, an obstruction of the tear duct, or the presence of a cyst in the tear drainage system. Patients were classified as having primary acquired obstruction of the tear duct if flushing the affected side with saline (before the onset of AD or after the infection calmed) showed a blockage. Monthly averages of data on temperature, humidity, pressure, and amount of precipitation were collected from the Royal Meteorological Institute of Belgium over the entire duration of the study. TAKEAWAY: Half of the patients had a blockage in the tear duct, 20% had no blockage, and the rest could not be classified because data on flushing were missing or incomplete. The incidence of AD rose significantly with age, with the risk increasing by 15.8% for every 5-year increase in age (exponentiated coefficient [Exp{B}], 1.158; P = .008). In patients with a blockage of the tear duct, the risk rose by 22.1% for every 5-year increase in age (Exp[B], 1.221; P = .002); however, no association was observed between increased age and the risk for AD in patients with an open tear passage. The incidence of AD was not statistically linked to any changes in the abovementioned weather conditions during the 14 days prior to infection onset. IN PRACTICE: The elevated risk for AD in older women with primary acquired nasolacrimal duct obstruction suggests the threshold to perform dacryocystorhinostomy should be lower for these patients, the researchers wrote. They proposed age 70 years as when clinicians should consider preventive dacryocystorhinostomy in patients with symptoms of primary acquired nasolacrimal duct obstruction, such as epiphora or mucocele. SOURCE: This study was led by Amber Demeuleneere of the Department of Ophthalmology at the University Hospitals Leuven, Leuven, Belgium. It was published online on June 18, 2025, in British Journal of Ophthalmology. LIMITATIONS: Mostly patients with severe AD were seen at the referral center. Those with blockage of the tear duct were not followed up over time. The use of weather averages on a monthly basis may have masked the effects of shorter durations of weather phenomena. DISCLOSURES: No grant support was received for this study. No relevant conflicts of interest were disclosed. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
a day ago
- Health
- Yahoo
Kodiak Sciences, Genentech, and AbbVie Drive Innovations Through Advanced, Sustainable Solutions
The global age-related vision dysfunction (ARVD) market is witnessing robust growth due to the aging population and heightened awareness of eye health. Age-related vision dysfunction encompasses impairments like macular degeneration, cataracts, and glaucoma, affecting quality of life. The market is thriving with innovative solutions, including pharmaceuticals, surgeries, and digital health technologies such as AI diagnostics and telemedicine. Despite economic and regulatory hurdles, advancements in treatments and strong investments from key players like Kodiak Sciences, Genentech, and AbbVie are driving market expansion. Growing demand in regions like Asia-Pacific offers promising opportunities. Dublin, June 24, 2025 (GLOBE NEWSWIRE) -- The "Age-Related Vision Dysfunction Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" report has been added to offering. Global age-related vision dysfunction (ARVD) market is on track for sustained growth, driven by the aging population, increasing awareness of age-related vision disorders, and the development of innovative treatments. Ongoing advancements in surgical technologies, pharmaceuticals, and diagnostic tools will continue to reshape the market's future. As demand for vision care solutions rises, both global and regional players will be key in meeting the evolving needs of individuals and healthcare systems, improving the quality of life for those affected by age-related vision dysfunction. The global age-related vision dysfunction market is experiencing significant growth as the prevalence of vision-related disorders continues to rise, driven by an aging population, increased longevity, and growing awareness about the importance of preserving eye health. The age-related vision dysfunction market plays a vital role in improving the quality of life for individuals suffering from age-related vision loss, providing them with a range of treatment options and solutions that enhance comfort, independence, and visual functionality. Treatment solutions in the age-related vision dysfunction market include a wide variety of therapeutic approaches such as pharmaceutical treatments, surgical interventions, corrective eyewear, and innovative vision aids, all designed to manage and alleviate the impact of conditions like age-related macular degeneration, cataracts, and the age-related vision dysfunction (ARVD) market evolves, emerging trends such as the integration of advanced diagnostic technologies like AI-driven retinal imaging, the growing adoption of minimally invasive treatment methods, and the development of long-acting injectable therapies will shape its future landscape. The continued demand for more affordable, accessible, and effective vision care treatments, particularly in emerging markets with rapidly aging populations, will present significant opportunities for growth in the years ahead. The competitive landscape of the global age-related vision dysfunction (ARVD) market is diverse, with numerous players across different regions offering a wide range of products. Regional players and local manufacturers are expected to play an important role in the market's growth, especially as demand increases in emerging markets such as Asia-Pacific and Latin America. As consumer preferences shift towards more discreet, comfortable, and affordable solutions, the age-related vision dysfunction (ARVD) market will continue to evolve, fostering new opportunities for both established and emerging players in the global age-related vision dysfunction (ARVD) market, such as Kodiak Sciences, Genentech, and AbbVie, Inc., are continuously innovating to improve the effectiveness and comfort of products. These companies are investing heavily in research and development to introduce new, technologically advanced solutions that cater to market growth. With a strong emphasis on user-friendly and environmentally sustainable products, these companies are shaping the future of age-related vision dysfunction (ARVD) while enhancing their market positions globally. As healthcare systems evolve to meet the needs of an aging population, the age-related vision dysfunction market is becoming an increasingly critical area of focus. The rising demand for effective vision correction and disease management solutions is fueled by the growing awareness of the importance of eye health in maintaining overall well-being. The market is expanding as both healthcare providers and consumers seek high-quality, reliable solutions for managing vision impairment. In particular, advancements in surgical techniques, pharmacological treatments, and non-invasive diagnostic technologies are boosting the market's growth as they offer more effective and less invasive methods for treating age-related vision dysfunction-related conditions.A key driver of the age-related vision dysfunction market is the rapidly increasing geriatric population, which is more susceptible to age-related eye conditions. As life expectancy continues to rise globally, the number of individuals experiencing age-related vision loss continues to grow, placing significant pressure on healthcare systems. This demographic shift is driving the demand for effective and accessible vision care solutions. Furthermore, innovations in treatment options, such as longer-lasting injectable therapies for macular degeneration and advanced cataract surgery techniques, are enhancing market growth by improving patient outcomes and reducing recovery addition to medical advancements, the integration of digital health solutions such as telemedicine, AI-driven diagnostics, and wearable devices is drastically improving access to eye care services, particularly in underserved regions. These innovations not only make care more accessible and affordable but also enhance the accuracy of diagnosis and the effectiveness of treatments. As these technologies continue to evolve, they will play a central role in managing age-related vision dysfunctions, improving patient outcomes, and reducing the burden on healthcare the positive market trajectory, several challenges continue to affect the age-related vision dysfunction (ARVD) market. One of the primary barriers is the high cost of treatments and surgical interventions, which can be a significant concern for patients in low-income regions or those without sufficient insurance coverage. The financial burden of these therapies can limit accessibility, particularly in developing markets. Additionally, there are ongoing challenges with early diagnosis and the underreporting of vision-related symptoms, which can delay treatment and result in worsened age-related vision dysfunction (ARVD) market is also facing regulatory challenges, as the approval processes for new treatments and devices can be lengthy and complex. However, continued innovations in product development, such as the use of regenerative therapies, advancements in ocular drug delivery systems, and the introduction of personalized treatments, are expected to drive sustained market growth. Companies are increasingly focused on developing solutions that meet the evolving needs of patients, including those that offer improved comfort, effectiveness, and reduced side effects, ultimately contributing to the market's expansion in the coming years. Competitive Landscape Genentech Kodiak Sciences Outlook Therapeutics AbbVie, Inc. Alimera Science Key Topics Covered:1. Markets: Industry Outlook1.1 Introduction1.2 Market Trends1.3 Regulatory Framework1.4 Clinical Trial Analysis1.5 Epidemiology of Age-Related Vision Dysfunction1.6 Market Dynamics1.6.1 Impact Analysis1.6.2 Market Drivers1.6.3 Market Challenges1.6.4 Market Opportunities2. Global Age-Related Vision Dysfunction Market, by Region, $Million, 2023-20352.1 North America2.1.1 Key Findings2.1.2 Market Dynamics2.1.3 Market Sizing and Forecast2.1.3.1 North America Age-Related Vision Dysfunction Market, by Country2.1.3.1.1 U.S.2.2 Europe2.2.1 Key Findings2.2.2 Market Dynamics2.2.3 Market Sizing and Forecast2.2.3.1 Europe Age-Related Vision Dysfunction Market, by Country2.2.3.1.1 Germany2.2.3.1.2 U.K.2.2.3.1.3 France2.2.3.1.4 Italy2.2.3.1.5 Spain2.3 Asia Pacific2.3.1 Key Findings2.3.2 Market Dynamics2.3.3 Market Sizing and Forecast2.3.3.1 Asia Pacific Age-Related Vision Dysfunction Market, by Country2.3.3.1.1 Japan3. Global Age-Related Vision Dysfunction Market: Competitive Landscape and Company Profiles3.1 Key Strategic Developments3.1.1 Mergers and Acquisitions3.1.2 Synergistic Activities3.1.3 Business Expansions and Funding3.1.4 Product Launches and Approvals3.1.5 Other Activities3.2 Company Profiles3.2.1 Overview3.2.2 Top Products / Product Portfolio3.2.3 Target Customers/End-Users3.2.4 Key Personnel3.2.5 Analyst View4. Research MethodologyFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Daily Mail
2 days ago
- Health
- Daily Mail
Doctor issues warning over make-up favourite that can trigger an agonising eye condition
Using a particular type of cosmetic could leave you with an agonising eye condition, medics have warned. Dr Jacqueline Beltz, an Australian ophthalmologist, said people should steer clear of waterproof make-up as it can lead to severe eye dryness. This painful condition leaves sufferers with burning, stinging, redness in their eyes as well as blurred vision. In a video posted on TikTok that has amassed over 500,000 views, Dr Beltz said she recommended her patients never use waterproof mascara due to how the ingredients—which help give the make-up its staying power—put your eyes at risk. 'They have a lot of drying qualities because you need the mascara to dry out and stay on your lashes, but it can also dry out your tear film,' she said. The tear film is the delicate thin layer of fluids on the surface of the eye that help keep the organ moist and help protect its sensitive tissue for external substances. Dr Beltz added: 'A lot of people with sensitive eyes have dry tear film already, so they don't need that extra dryness. @okkiyoeyes Busted, our operations manager Mikyla's officially in the bad books 😂 Why the drama? Waterproof mascara isn't just drying on your lashes, it can dry out your tear film, too. Yep, the actual thing that keeps your eyes comfy and hydrated. The more you know! #SensitiveEyes #Mascara #JacquiSaidNo ♬ original sound - OKKIYO 'The second reason is because it is obviously just harder to get off. So not only do you need stronger chemicals, but more rubbing, which can be irritating if you have sensitive eyes.' Social media users were left shocked about the dangers, with some saying it might explain why they've been suffering years of eye problems. One wrote: 'So that's why my eyes get really itchy when I wear waterproof mascara.' Another added: 'I wear waterproof mascara and have had dry eyes since 2016 and no one has told me about this! I'm going to change my mascara ASAP.' And a third wrote: 'I have had issues with my eyes for some time now and no one has recommended this despite me asking my specialist and optometrist.' Dr Beltz isn't the only eye expert to warn about the dangers of waterproof make-up. Reacting to her clip on Instagram, Dr Julian Prosia, a Canadian optometrist, also urged people to stay away from this type of cosmetic. 'While make-up in general can lead to more dry eye issues and even irritation on the eye the waterproof make-up type is the worst thing you can do when it comes to meibomian gland dysfunction,' he said. Meibomian gland dysfunction is a common eye condition where the glands that help maintain the tear film become damaged, causing dry eyes. As such, Dr Prosia urged people to choose 'healthier' cosmetics such water soluble options as well make-up brands recommended by eye-health specialists. But he added waterproof make-up wasn't the only type of cosmetic people should be wary of when it came to maintaining their eye health. Dr Prosia directed viewers to a list made by Dr Huda Minhas, from the University of Puerto Rico, on commonly ingredients to be cautious of. One worrying chemical, which can be found in waterproof mascara, was Butylated hydroxyanisole. The chemical is classified as a possible human carcinogen by the International Agency for Research on Cancer, Dr Minhas warned. Other make-up ingredients she listed to beware of include benzalkonium chloride which she said can kill the meibomian glands within 15 minutes, even at low levels. Another was the chemical formaldehyde which Dr Minhas said could trigger dermatitis, skin and eye surface irritation and even cancers. She added that parabens—a type of preservative found in some cosmetics—can dispurt natural hormone function and are known to prevent the meibomian glands from working correctly. Phenoxyethanol, another preservative, is also known to cause eye irritation and painful skin problems, she added. It follows a warning from Breast Cancer UK earlier this year that toiletries used by millions of women daily could increase their chances of developing breast cancer. The charity said shampoos and face creams contain substances—that while safe in isolation—can combine on the skin to produce endocrine disrupting chemicals. These chemicals interfere with the human hormone system and have been linked to an increased risk of breast cancer. The charity warned that woman using many beauty or hygiene products in a single day are unknowingly creating a powerful 'chemical cocktail'. Breast Cancer UK estimated the average British woman is exposed to over 150 potentially harmful chemicals as part of their daily beauty regime.
Globe and Mail
04-06-2025
- Business
- Globe and Mail
Global Ophthalmic Implants Market Revenue to Reach USD 8.14 billion by 2030 – Exclusive Research by Focus Reports
"Global Ophthalmic Implants Market Revenue to Reach USD 8.14 billion by 2030 - Exclusive Research by Focus Reports" Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2025–2030. According to Focus Report's latest research report, the global ophthalmic implants market is growing at a CAGR of 7.48% during 2021-2030. Looking for More Information? Click: Report Scope: Market Size (2030): USD 8.14 Billion Market Size (2024): USD 5.28 Billion CAGR (2024-2030): 7.48% Historic Year: 2021-2023 Base Year: 2024 Forecast Year: 2025-2030 Largest Region (2024): North America Fastest-Growing Region: Asia Pacific Market Segmentation: Product, Application, End-Users, and Geography Geographic Analysis: North America, Europe, APAC, Latin America, and the Middle East & Africa Market Overview The global ophthalmic implants market is evolving rapidly, driven by the increasing burden of eye diseases, a growing ageing population, and rising healthcare expenditure dedicated to vision care. Eye health continues to be a critical global concern, with leading organizations such as the World Health Organization (WHO), the International Agency for the Prevention of Blindness (IAPB), and the American Academy of Ophthalmology, along with numerous regional and national health authorities, playing an active role in promoting eye care awareness and access to surgical interventions. The COVID-19 pandemic significantly disrupted the ophthalmology landscape, resulting in widespread delays and cancellations of elective eye surgeries and consultations. This disruption led to a notable slowdown in the ophthalmic implants market between 2019 and 2020, with a substantial decline in surgical volumes and overall market revenues. However, easing restrictions in 2021 led to a surge in postponed procedures, boosting demand for ophthalmic implants. After a slight dip in 2022 as backlogs cleared, the market has stabilized since 2023 and is expected to maintain consistent growth supported by ongoing innovations and rising patient awareness. Growing Adoption of Synthetic Corneal Implants Expands Treatment Options for High-Risk Patients The growing use of synthetic corneal implants is bringing new hope to patients suffering from corneal blindness, especially those who cannot undergo traditional corneal transplants. While donor cornea transplants work well for many, they often fail in patients with conditions like chronic inflammation, glaucoma, herpes infections, or excessive blood vessel growth in the cornea. In addition, the global demand for donor corneas far exceeds supply, particularly in developing countries. Synthetic corneal implants, known as keratoprostheses, offer an effective alternative. According to the Cornea Research Foundation of America (2025), these fully artificial implants are now widely available and are helping restore vision in patients who are not suitable for human donor transplants. With an estimated 11 million people worldwide affected by bilateral corneal blindness (2022), this advancement is making treatment more accessible, reducing wait times, and improving outcomes for those most in need. By offering a reliable solution where traditional methods fall short, synthetic implants are enhancing care and quality of life for patients around the world. Rising Adoption of Advanced Ocular Devices Opens New Horizons in Eye Care Market The eye implant market is witnessing significant momentum, driven by the rising acceptance of advanced ocular technologies such as artificial eyes and glaucoma management devices. This growing adoption is being further supported by a surge in regulatory approvals, enabling leading manufacturers to expand their product portfolios and capitalize on new revenue streams. Ongoing investments in R&D are paving the way for next-generation eye care solutions, with cutting-edge ophthalmic diagnostics accelerating clinical acceptance and market penetration. Increased digital accessibility has also played a crucial role in patient education, empowering individuals to explore innovative treatment options and thereby boosting demand. One notable advancement gaining traction is the artificial corneal implant, which has emerged as a crucial alternative for patients unsuitable for human donor transplants. As highlighted by the Cornea Research Foundation of America (2023), while over 11 million people globally suffer from corneal blindness, only 100,000 receive donor-based implants, underscoring a critical gap and reinforcing the need for synthetic alternatives. The European Blind Union (2022) reports that nearly 30 million people in Europe are affected by visual impairments, driving the need for more frequent and sophisticated corneal procedures. With an aging population and rising expectations for high-quality eye care, the adoption of advanced ocular implants is expected to accelerate in the years ahead. Recent Vendor Activities In 2024, Alimera Sciences was acquired by ANI Pharmaceuticals to expand its footprint into the ophthalmology sector. This transaction is valued at around $381 million. Alimera Sciences was offered 2 ophthalmic implants that treat posterior eye diseases. In 2024, Johnson & Johnson Medtech- one of the global companies in eye health launched TECNIS PureSee (Intraocular Lens) to correct refractive presbyopia in Europe and the Middle East and Africa (EMEA). In 2024, Occular Therapeutix, a biopharmaceutical company, announced that the first patients had been enrolled in the phase 3 SOL-R clinical studies evaluating repeat dosing of the AXPAXLI implant for the treatment of a patient with wet AMD. Strategic Innovations and Collaborations Drive Expansion in Ophthalmic Implants Market In recent years, the global ophthalmic implants industry has experienced dynamic strategic activities, including mergers, acquisitions, and partnerships, aimed at expanding global footprints and accelerating product innovation. Leading companies such as Alcon, ZEISS Group, Bausch + Lomb, and Johnson & Johnson continue to dominate the market, offering advanced ophthalmic implant solutions that not only fulfill consumer needs but also adhere to stringent regulatory standards. These key players are enhancing product efficiency and solidifying their market positions through robust brand presence and extensive geographic reach worldwide. The competitive landscape has intensified as vendors increasingly deploy strategies like new product launches, strategic mergers and acquisitions, and the integration of cutting-edge technologies and materials into their offerings. A notable example includes Science Corporation's acquisition of Pixium's PRIMA Retinal Implants, marking a significant step in their commitment to vision restoration. While this innovative retinal implant is not yet commercially available, promising preliminary clinical trial results highlight the potential of emerging technologies to revolutionize ocular care and expand market opportunities. Key Vendors Alcon Carl Zeiss Bausch + Lomb Johnson & Johnson Other Prominent Vendors AJL Ophthalmic BVI Care Group CorNeat Vision Devine Meditech EyeD Pharma Ani Pharmaceuticals Eyedeal Medical Technology Company Limited Müller Söhne Gulden Ophthalmics Glaukos HumanOptics Hoya Corporation LambdaVision Labtician Ophthalmics MORCHER iSTAR Medical Ophtec Omni Lens Rayner Intraocular Lenses Limited SMR OPHTHALMIC Ocular Therapeutix F. Hoffmann-La Roche Market Segmentation & Forecast Product Intraocular Lenses Glaucoma Implants Corneal Implants Others Application Cataract Surgery Glaucoma Surgery Other Applications End-Users Hospitals Ophthalmic Clinics Other End-User Geography North America US Canada Europe Germany UK France Italy Spain APAC China Japan India Australia South Korea Latin America Brazil Mexico Argentina Middle East & Africa Turkey Saudi Arabia South Africa Other Related Reports that Might be of Your Business Requirement Global Contact Lenses Market - Focused Insights 2024-2029 Global Disposable Contact Lenses Market - Focused Insights 2024-2029 What Key Findings Will Our Research Analysis Reveal? How big is the global ophthalmic implants market? What are the factors driving the global ophthalmic implants market growth? Which product type will dominate the global ophthalmic implants market growth? Which region will have the highest growth in the global ophthalmic implants market? Who are the major players in the global ophthalmic implants market? What is the growth rate of the global ophthalmic implants market? Why Arizton? 100% Customer Satisfaction 24x7 availability – we are always there when you need us 200+ Fortune 500 Companies trust Arizton's report 80% of our reports are exclusive and first in the industry 100% more data and analysis 1500+ reports published till date Post-Purchase Benefit 1hr of free analyst discussion 10% off on customization About Us: Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services. We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts. Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.
